Whole-body hyperthermia combined with chemotherapy and intensity-modulated radiotherapy for treatment of advanced nasopharyngeal carcinoma: a retrospective study with propensity score matching

被引:12
|
作者
Zheng, Naiying [1 ]
Xu, Anan [1 ]
Lin, Xiantao [2 ]
Mo, Zhiwen [1 ]
Xie, Xiaoxue [3 ,4 ]
Huang, Zhong [1 ]
Liang, Ying [1 ]
Cai, Zhihua [5 ]
Tan, Jianming [1 ]
Shao, Xunfan [1 ]
机构
[1] Guangzhou Med Univ, Dept Radiotherapy, Affiliated Canc Hosp & Inst, Hengzhigan Rd 78, Guangzhou 510000, Peoples R China
[2] Hainan Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Haikou, Hainan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Radiotherapy, Xiangya Med Sch, Changsha, Peoples R China
[4] Cent South Univ, Affiliated Canc Hosp, Xiangya Med Sch, Changsha, Peoples R China
[5] Guangzhou Med Univ, Dept Chemotherapy, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
关键词
Whole-body hyperthermia; nasopharyngeal carcinoma; radiotherapy; chemotherapy; propensity sore matching; clinical trial; SQUAMOUS-CELL CARCINOMA; THERAPEUTIC-EFFICACY; CISPLATIN; COMBINATION; CANCER; HEAD; RADIATION; APOPTOSIS; OUTCOMES;
D O I
10.1080/02656736.2021.1971778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Several studies have reported the combination of intracavity or cervical lymph node hyperthermia with chemoradiotherapy (CRT) to improve clinical outcomes in nasopharyngeal carcinoma (NPC), but the combination with whole-body hyperthermia (WBH) for treating NPC is unexplored. We aimed to assess the efficacy of the combination of radiotherapy, chemotherapy and WBH in patients with locoregionally advanced NPC. Methods Between July 2008 and November 2012, 239 newly diagnosed NPC patients were enrolled in a pre-propensity score-matched cohort, including 193 patients who received CRT (CRT group) and 46 who underwent CRT with WBH (HCRT group). The feasibility and clinical outcomes of both groups were evaluated and toxicities assessed. Survival rates were assessed using the Kaplan-Meier method, log-rank test and Cox regression. Results Following propensity score matching, 46 patients from each group were included. The 5-year overall survival (OS) rates were 65.2% in the CRT group and 80.3% in the HCRT group (p=.027). In contrast, the other survival outcomes at 5 years were similar between the groups: locoregional recurrence-free survival (LRRFS), 74.7% vs. 87.6% (p=.152); distant metastasis-free survival (DMFS), 67.4% vs. 77.9% (p=.125); and progression-free survival (PFS), 53.1% vs. 69.2% (p=.115). In the multivariate analyses, the only two independent predictors of OS were clinical stage and HCRT. Conclusions These results suggest that WBH, when combined with CRT, can improve the OS of patients with advanced NPC.
引用
收藏
页码:1304 / 1312
页数:9
相关论文
共 50 条
  • [1] Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis
    Peng, Hao
    Chen, Lei
    Li, Wen-Fei
    Zhang, Yuan
    Liu, Li-Zhi
    Tian, Li
    Lin, Ai-Hua
    Sun, Ying
    Ma, Jun
    ORAL ONCOLOGY, 2016, 62 : 78 - 84
  • [2] Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis
    Chen, Jiawei
    Ding, Jianming
    Xu, Yiying
    Hong, Huiling
    Lin, Xiaoting
    Xu, Mengting
    Yan, Linghui
    Xu, Ting
    Fei, Zhaodong
    Chen, Chuanben
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (08)
  • [3] Efficacy of induction chemotherapy combined with chrono-chemotherapy and intensity-modulated radiotherapy on locally advanced nasopharyngeal carcinoma
    Zhang, Song
    Teng, Ting
    Liao, Guihua
    Liu, Yang
    Liu, Qingguo
    He, Wei
    Liu, Yan
    JOURNAL OF BUON, 2021, 26 (03): : 774 - 780
  • [4] Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
    Wang, Fangzheng
    Sun, Quanquan
    Jiang, Chuner
    Liu, Tongxin
    Rihito, Aizawa
    Masoto, Sakamoto
    Wang, Yuezhen
    Fu, Zhenfu
    Chen, Ming
    JOURNAL OF CANCER, 2018, 9 (03): : 594 - 603
  • [5] Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
    Huang, Jianfeng
    Zou, Qinzhou
    Qian, Danqi
    Zhou, Leyuan
    Yang, Bo
    Chu, Jianjun
    Pang, Qingfeng
    Wang, Kewei
    Zhang, Fuzheng
    ONCOTARGETS AND THERAPY, 2017, 10 : 5835 - 5841
  • [6] Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
    Qiu, Wen-Ze
    Huang, Pei-Yu
    Shi, Jun-Li
    Xia, Hai-Qun
    Zhao, Chong
    Cao, Ka-Jia
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [7] Prognostic value of nutritional markers in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy: a propensity score matching study
    Oei, Ronald Wihal
    Ye, Lulu
    Huang, Juan
    Kong, Fangfang
    Xu, Tingting
    Shen, Chunying
    Wang, Xiaoshen
    He, Xiayun
    Kong, Lin
    Hu, Chaosu
    Ying, Hongmei
    ONCOTARGETS AND THERAPY, 2018, 11 : 4857 - 4868
  • [8] Intensity-modulated radiotherapy combined with sequential cisplatin and fluorouracil chemotherapy for locoregionally advanced nasopharyngeal carcinoma
    Wu, Mingyao
    He, Xiayun
    Hu, Chaosu
    MEDICINE, 2018, 97 (50)
  • [9] A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy
    Slevin, F.
    Pan, S.
    Mistry, H.
    Sen, M.
    Foran, B.
    Slevin, N.
    Dixon, L.
    Thomson, D.
    Prestwich, R.
    CLINICAL ONCOLOGY, 2020, 32 (04) : 238 - 249
  • [10] Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy
    Zeng, Lei
    Guo, Pi
    Li, Jin-Gao
    Han, Fei
    Li, Qiang
    Lu, Yong
    Deng, Xiao-Wu
    Zhang, Qing-Ying
    Lu, Tai-Xiang
    ONCOTARGET, 2015, 6 (36) : 39373 - 39383